Vivani Medical (VANI) Projected to Post Earnings on Wednesday

Vivani Medical (NASDAQ:VANI) will likely be releasing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.08) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Vivani Medical (NASDAQ:VANI) last announced its earnings results on Wednesday, May 13th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). On average, analysts expect Vivani Medical to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Vivani Medical Price Performance

VANI stock opened at $1.43 on Wednesday. The business has a fifty day moving average price of $1.28 and a 200 day moving average price of $1.24. Vivani Medical has a fifty-two week low of $0.92 and a fifty-two week high of $1.92. The stock has a market capitalization of $122.89 million, a price-to-earnings ratio of -3.56 and a beta of 2.35.

Insiders Place Their Bets

In other news, Director Gregg Williams acquired 1,587,301 shares of the stock in a transaction dated Monday, June 15th. The shares were bought at an average cost of $1.26 per share, for a total transaction of $1,999,999.26. Following the purchase, the director directly owned 36,119,086 shares of the company’s stock, valued at approximately $45,510,048.36. This trade represents a 4.60% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 53.30% of the company’s stock.

Hedge Funds Weigh In On Vivani Medical

Large investors have recently modified their holdings of the stock. Tudor Investment Corp ET AL bought a new position in Vivani Medical in the 4th quarter valued at about $1,127,000. Geode Capital Management LLC increased its position in Vivani Medical by 29.6% during the 4th quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock worth $568,000 after buying an additional 105,398 shares during the period. State Street Corp boosted its position in shares of Vivani Medical by 12.5% in the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock valued at $178,000 after acquiring an additional 16,070 shares during the period. Marshall Wace LLP bought a new position in Vivani Medical during the fourth quarter worth about $174,000. Finally, Renaissance Technologies LLC boosted its holdings in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares during the period. 6.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

VANI has been the topic of several research reports. Weiss Ratings upgraded shares of Vivani Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 7th. Lake Street Capital assumed coverage on shares of Vivani Medical in a research report on Tuesday, June 23rd. They set a “buy” rating and a $4.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.75.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.